The metabolic syndrome: time for a critical appraisal

[1]  M. Laakso,et al.  Cardiovascular disease risk factors as predictors of Type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects , 1993, Diabetologia.

[2]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[3]  T. Lumley,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.

[4]  D. Giugliano,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.

[5]  T. Dinan,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.

[6]  D. Cheța The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. , 2006, Diabetes care.

[7]  Paul Zimmet,et al.  [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. , 2005, Revista espanola de cardiologia.

[8]  L. Chambless,et al.  Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. , 2005, Diabetes.

[9]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[10]  C. Polman,et al.  Effect of rimonabant on weight reduction and cardiovascular risk , 2005, The Lancet.

[11]  E. Gale The myth of the metabolic syndrome , 2005, Diabetologia.

[12]  Laura M. Stapleton,et al.  Re: "(Mis)use of factor analysis in the study of insulin resistance syndrome". , 2005, American journal of epidemiology.

[13]  H. Kolb,et al.  The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. , 2005, European journal of endocrinology.

[14]  K. Hunt,et al.  Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. , 2005, Atherosclerosis. Supplements.

[15]  S. Fowler,et al.  The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial , 2005, Annals of Internal Medicine.

[16]  E. Lakatta,et al.  The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. , 2005, Diabetes care.

[17]  Ralph D'Agostino,et al.  Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors , 2005, Annals of Internal Medicine.

[18]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[19]  Ken Williams,et al.  Identification of individuals with insulin resistance using routine clinical measurements. , 2005, Diabetes.

[20]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[21]  Piero Avogaro,et al.  Associazione di iperlipemia, diabete mellito e obesita' di medio grado , 1967, Acta diabetologia latina.

[22]  A. H. Kadish Cybernetics of blood sugar and fat in health and disease , 2005, Acta diabetologia latina.

[23]  D. Lawlor,et al.  (Mis)use of factor analysis in the study of insulin resistance syndrome. , 2005, American journal of epidemiology.

[24]  S. Haffner,et al.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.

[25]  A. Biggeri,et al.  Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. , 2004, Diabetes care.

[26]  J. Tuomilehto,et al.  The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a chinese population with high postprandial glucose. , 2004, Diabetes care.

[27]  R. Marfella,et al.  Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. , 2004, JAMA.

[28]  Ken Williams,et al.  National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study , 2004, Circulation.

[29]  Nathan D. Wong,et al.  Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults , 2004, Circulation.

[30]  M. Reilly,et al.  Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary Atherosclerosis , 2004, Circulation.

[31]  Jane B Shofer,et al.  Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. , 2004, Diabetes.

[32]  M. Rutter,et al.  C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in the Framingham Offspring Study , 2004, Circulation.

[33]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[34]  Arvind Shah,et al.  Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). , 2004, Diabetes care.

[35]  John Horgan,et al.  Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. , 2004, Circulation.

[36]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[37]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[38]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[39]  S. Blair,et al.  Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. , 2004, Archives of internal medicine.

[40]  C. Lamendola,et al.  Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. , 2004, Diabetes.

[41]  E. Ford The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.

[42]  J. Peters,et al.  Evaluating the performance of the Framingham risk equations in a population with diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[43]  A. Jenkins,et al.  Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. , 2004, Diabetes care.

[44]  P. M. Brown,et al.  Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[45]  S. Reis,et al.  Metabolic Syndrome Modifies the Cardiovascular Risk Associated With Angiographic Coronary Artery Disease in Women: A Report From the Women’s Ischemia Syndrome Evaluation , 2004, Circulation.

[46]  S. Grundy,et al.  Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[47]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[48]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[49]  A. Gotto,et al.  The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2004, The American journal of cardiology.

[50]  M. Stern,et al.  The insulin resistance syndrome: the controversy is dead, long live the controversy! , 1994, Diabetologia.

[51]  L. Welin,et al.  Hyperinsulinaemia is not a major coronary risk factor in elderly men , 1992, Diabetologia.

[52]  S. Haffner,et al.  Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome , 1991, Diabetologia.

[53]  A. Fontbonne,et al.  Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up , 1991, Diabetologia.

[54]  P. Ducimetiere,et al.  Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population , 1980, Diabetologia.

[55]  T. S. Group Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies , 2004 .

[56]  Lex M. Bouter,et al.  Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies , 2004, Diabetologia.

[57]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[58]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[59]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[60]  Tracey McLaughlin,et al.  Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant , 2003, Annals of Internal Medicine.

[61]  M. Jensen,et al.  Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. , 2003, Diabetes care.

[62]  M. Davidson Is treatment of insulin resistance beneficial independent of glycemia? , 2003, Diabetes care.

[63]  Richard Hellman,et al.  American College of Endocrinology position statement on the insulin resistance syndrome. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[64]  S. Grundy,et al.  The metabolic syndrome: a practical guide to origins and treatment: Part II. , 2003, Circulation.

[65]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[66]  R. D'Agostino,et al.  Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. , 2003, Diabetes.

[67]  R. Henry,et al.  Adiponectin: more than just another fat cell hormone? , 2003, Diabetes care.

[68]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[69]  S. Kihara,et al.  Erratum , 2003, Heart.

[70]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[71]  S. Teutsch,et al.  NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. , 2003, Diabetes.

[72]  Avron Spiro,et al.  Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. , 2003, American journal of epidemiology.

[73]  J. Manson,et al.  C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[74]  E. Ford,et al.  A comparison of the prevalence of the metabolic syndrome using two proposed definitions. , 2003, Diabetes care.

[75]  B. Howard,et al.  Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study. , 2003, Diabetes care.

[76]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[77]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[78]  P. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[79]  S. Kihara,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[80]  S. Teutsch,et al.  THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .

[81]  See S Hadid Is Treatment of Insulin Resistance Beneficial Independent of Glycemia , 2003 .

[82]  E. Ford,et al.  Factor analysis and defining the metabolic syndrome. , 2003, Ethnicity & disease.

[83]  S. Grundy,et al.  The metabolic syndrome: practical guide to origins and treatment: Part I. , 2003, Circulation.

[84]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[85]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[86]  C. Lamendola,et al.  Differentiation Between Obesity and Insulin Resistance in the Association With C-Reactive Protein , 2002, Circulation.

[87]  A. Onat,et al.  Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. , 2002, Atherosclerosis.

[88]  C. Zoccali,et al.  Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. , 2002, Journal of the American Society of Nephrology : JASN.

[89]  J. Brunzell,et al.  Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[90]  P. Nilsson,et al.  Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.

[91]  Ronald Klein,et al.  Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. , 2002, Diabetes care.

[92]  Moyses Szklo,et al.  Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. , 2002, Diabetes.

[93]  B. Balkau,et al.  Insulin: in search of a syndrome , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[94]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[95]  P. Savage,et al.  Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. , 2002, Diabetes.

[96]  S. Maruoka,et al.  Decreased plasma adiponectin concentrations in women with dyslipidemia. , 2002, The Journal of clinical endocrinology and metabolism.

[97]  G. Yoshino,et al.  Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. , 2002, Diabetes care.

[98]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[99]  Sc Prospective,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002 .

[100]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[101]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[102]  N. Day,et al.  Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. , 2001, Diabetes care.

[103]  M. Laakso,et al.  Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. , 2001, Diabetes care.

[104]  G. Reaven,et al.  Insulin resistance as a predictor of age-related diseases. , 2001, The Journal of clinical endocrinology and metabolism.

[105]  K. Yeo,et al.  Predicting CHD risk in patients with diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[106]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[107]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[108]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[109]  H. Lebovitz,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .

[110]  C. Bogardus,et al.  A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. , 2000, Diabetes.

[111]  P. Wahl,et al.  Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. , 2000, American journal of epidemiology.

[112]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[113]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[114]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[115]  S. Haffner,et al.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. , 2000, Circulation.

[116]  G. Reaven,et al.  Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. , 2000, Diabetes care.

[117]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[118]  M. Laakso,et al.  Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.

[119]  M. Laakso,et al.  Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[120]  M. Laakso,et al.  Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. , 1999, Circulation.

[121]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[122]  M. Rewers,et al.  Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. , 1999, Diabetes care.

[123]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[124]  S. Haffner,et al.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[125]  M. Laakso,et al.  Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. , 1999, Diabetes care.

[126]  P. Savage,et al.  Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. , 1998, American journal of epidemiology.

[127]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[128]  M. Laakso,et al.  Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 1998, Circulation.

[129]  G. Reaven,et al.  Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. , 1998, The Journal of clinical endocrinology and metabolism.

[130]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[131]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[132]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[133]  G. Riccardi,et al.  Plasma Fibrinogen: A New Factor of the Metabolic Syndrome: A population-based study , 1998, Diabetes Care.

[134]  P. Sweetnam,et al.  Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies , 1998, Heart.

[135]  S. Haffner,et al.  Development of the multiple metabolic syndrome: an epidemiologic perspective. , 1998, Epidemiologic reviews.

[136]  Ralph B D'Agostino,et al.  Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study , 1997, Diabetes.

[137]  R N Bergman,et al.  Low insulin sensitivity is associated with clustering of cardiovascular disease risk factors. , 1997, American journal of epidemiology.

[138]  A. Folsom,et al.  A Prospective Study of Coronary Heart Disease in Relation to Fasting Insulin, Glucose, and Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 1997, Diabetes Care.

[139]  P. Whincup,et al.  Serum insulin and incident coronary heart disease in middle-aged British men. , 1996, American journal of epidemiology.

[140]  P. Metcalf,et al.  Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. , 1996, Metabolism: clinical and experimental.

[141]  R. Bergman,et al.  Insulin Sensitivity and Atherosclerosis , 1996 .

[142]  B. Duncan,et al.  A Metabolic Syndrome in Whites and African-Americans: The Atherosclerosis Risk in Communities baseline study , 1996, Diabetes Care.

[143]  G. Dagenais,et al.  Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.

[144]  K. Polonsky,et al.  Report of the American Diabetes Association's Task Force on Standardization of the Insulin Assay , 1996, Diabetes.

[145]  R. Bergman,et al.  Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1996, Circulation.

[146]  P. McKeigue,et al.  Associations Between Insulin Levels and Cardiovascular Disease Are Confounded by Comorbidity , 1995, Diabetes Care.

[147]  E. Barrett-Connor,et al.  Is Insulin Really a Heart Disease Risk Factor? , 1995, Diabetes Care.

[148]  G. Reaven,et al.  Pathophysiology of insulin resistance in human disease. , 1995, Physiological reviews.

[149]  J. Jespersen,et al.  Fasting Serum Insulin Levels and Coronary Heart Disease in a Danish Cohort: 17-year Follow-up , 1995, Journal of cardiovascular risk.

[150]  B. Fagerberg,et al.  Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. , 1995, Stroke.

[151]  E. Barrett-Connor,et al.  Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo Study, 1984-1991. , 1994, American journal of epidemiology.

[152]  L. Kuller,et al.  Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. , 1994, Annals of epidemiology.

[153]  Donald A. Smith Fibrinogen as a cardiovascular risk factor: a meta-analysis , 1993, ACP Journal Club.

[154]  M. Blankenstein,et al.  The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. , 1993, Metabolism: clinical and experimental.

[155]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[156]  J. Després,et al.  Abdominal obesity as important component of insulin-resistance syndrome. , 1993, Nutrition.

[157]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[158]  G. Reaven,et al.  Evidence for an independent relationship between insulin resistance and fasting plasma HDL‐cholesterol, triglyceride and insulin concentrations , 1992, Journal of internal medicine.

[159]  M. Laakso,et al.  Asymptomatic atherosclerosis and insulin resistance. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[160]  L. Niskanen,et al.  5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990, Circulation.

[161]  M. Laakso,et al.  Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. , 1990, Arteriosclerosis.

[162]  M. IUusitupa,et al.  5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990 .

[163]  M. Saad,et al.  Insulin resistance in essential hypertension. , 1990, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[164]  L. Wilhelmsen,et al.  Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. , 1989, BMJ.

[165]  E. Bonora,et al.  Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. , 1989, The New England journal of medicine.

[166]  R. Warnke,et al.  Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. , 1989, The New England journal of medicine.

[167]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[168]  R. DeFronzo The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[169]  S. Haffner,et al.  Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. , 1988, Metabolism: clinical and experimental.

[170]  S. Haffner,et al.  Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. , 1986, Arteriosclerosis.

[171]  H. Halkin,et al.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.

[172]  L H Kuller,et al.  Plasma insulin and lipoprotein concentrations: an atherogenic association? , 1983, American journal of epidemiology.

[173]  J. E. Jackson,et al.  Factor analysis, an applied approach , 1983 .

[174]  E. Barrett-Connor,et al.  Clustering of heart disease risk factors in diabetic compared to nondiabetic adults. , 1983, American journal of epidemiology.

[175]  J. A. Scarlett,et al.  Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. , 1982, The American journal of physiology.

[176]  A. Gotto,et al.  Relationship of hypertriglyceridemia to atherosclerosis. , 1981, Arteriosclerosis.

[177]  M. Shipley,et al.  CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.

[178]  T. Welborn,et al.  Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations , 1979, Diabetes Care.

[179]  D L McGee,et al.  Diabetes and Cardiovascular Risk Factors: The Framingham Study , 1979, Circulation.

[180]  K. Pyörälà,et al.  Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. , 1979, Diabetes care.

[181]  H. Haller [Epidermiology and associated risk factors of hyperlipoproteinemia]. , 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.

[182]  P. Singer [Diagnosis of primary hyperlipoproteinemias]. , 1977, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete.

[183]  G. Reaven,et al.  Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. , 1975, The Journal of clinical investigation.

[184]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[185]  G. Reaven,et al.  Reappraisal of the role of insulin in hypertriglyceridemia. , 1974, The American journal of medicine.

[186]  H. Blackburn,et al.  Coronary heart disease: overweight and obesity as risk factors. , 1972, Annals of internal medicine.

[187]  G. Reaven,et al.  Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. , 1970, The Journal of clinical investigation.

[188]  G. Reaven,et al.  Role of insulin in endogenous hypertriglyceridemia. , 1967, The Journal of clinical investigation.

[189]  Copeman Pw,et al.  THE AMERICAN AND HIS DIET. , 1964 .

[190]  H. Himsworth DIABETES MELLITUS: ITS DIFFERENTIATION INTO INSULIN-SENSITIVE AND INSULIN-INSENSITIVE TYPES , 1936 .